Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
14,628
Total Claims
$6.6M
Drug Cost
566
Beneficiaries
$12K
Cost/Patient
Risk Score Breakdown 16/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
-70%
Opioid rate vs peers
0.8% vs 2.6% avg
+995%
Cost per patient vs peers
$12K vs $1,068 avg
+157%
Brand preference vs peers
23.1% vs 9.0% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
🔎 Data Overview
Cost per patient is 995% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.8%
Opioid Rate
115
Opioid Claims
$1,321
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 3,244 claims · $5.7M
Generic: 10,777 claims · $872K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Diclofenac Sodium | 248 | $1.9M |
| Diclofenac Sodium | 401 | $625K |
| Lipase/Protease/Amylase | 92 | $515K |
| Ibuprofen/Famotidine | 39 | $291K |
| Sitagliptin Phosphate | 126 | $202K |
| Budesonide/Formoterol Fumarate | 222 | $193K |
| Metformin Hcl | 85 | $191K |
| Dulaglutide | 65 | $150K |
| Insulin Aspart | 118 | $139K |
| Linagliptin | 83 | $125K |
| Prednisone | 11 | $115K |
| Linaclotide | 88 | $111K |
| Apixaban | 66 | $97K |
| Icosapent Ethyl | 89 | $90K |
| Ibuprofen/Famotidine | 103 | $86K |
Prescribing Profile
Patient Profile
71
Avg Age
67%
Female
1.55
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data